Prostate cancer (PCa) is the most common malignancy worldwide in men. This is a proof-of-concept study describing the development of Ga-magnetic iron oxide nanoparticles (mNP) targeting prostate specific membrane antigen (PSMA) and gastrin releasing peptide (GRPR) receptors as potential tools for diagnosis of PCa with PET/MRI. Two pharmacophores targeting PSMA, 1, and GRPR, 2, were coupled to mNPs carrying -SH (mNP-S1/2) or -NH (mNP-N1/2) groups.
View Article and Find Full Text PDF